Immix Biopharma Inc. (IMMX)
Immix Biopharma Statistics
Share Statistics
Immix Biopharma has 27.72M shares outstanding. The number of shares has increased by 4.95% in one year.
| Shares Outstanding | 27.72M |
| Shares Change (YoY) | 4.95% |
| Shares Change (QoQ) | 0.78% |
| Owned by Institutions (%) | 9.76% |
| Shares Floating | 16.51M |
| Failed to Deliver (FTD) Shares | 7.6K |
| FTD / Avg. Volume | 11.12% |
Short Selling Information
The latest short interest is 434.94K, so 1.58% of the outstanding shares have been sold short.
| Short Interest | 434.94K |
| Short % of Shares Out | 1.58% |
| Short % of Float | 2.65% |
| Short Ratio (days to cover) | 2.94 |
Valuation Ratios
The PE ratio is -2.88 and the forward PE ratio is -2.86. Immix Biopharma's PEG ratio is 0.2.
| PE Ratio | -2.88 |
| Forward PE | -2.86 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 4.7 |
| P/FCF Ratio | -3.95 |
| PEG Ratio | 0.2 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Immix Biopharma.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.33, with a Debt / Equity ratio of 0.08.
| Current Ratio | 2.33 |
| Quick Ratio | 2.33 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | -0.05 |
| Debt / FCF | -0.07 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.2M |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 41.04K |
| Effective Tax Rate | -0.19% |
Stock Price Statistics
The stock price has increased by -45.42% in the last 52 weeks. The beta is 0.25, so Immix Biopharma's price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | -45.42% |
| 50-Day Moving Average | 1.82 |
| 200-Day Moving Average | 1.92 |
| Relative Strength Index (RSI) | 43.21 |
| Average Volume (20 Days) | 68.32K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -22.67M |
| Net Income | -21.61M |
| EBITDA | -22.67M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.76 |
Balance Sheet
The company has 17.68M in cash and 1.07M in debt, giving a net cash position of 16.61M.
| Cash & Cash Equivalents | 17.68M |
| Total Debt | 1.07M |
| Net Cash | 16.61M |
| Retained Earnings | -75.02M |
| Total Assets | 22.95M |
| Working Capital | 11.51M |
Cash Flow
In the last 12 months, operating cash flow was -14.6M and capital expenditures -1.18M, giving a free cash flow of -15.77M.
| Operating Cash Flow | -14.6M |
| Capital Expenditures | -1.18M |
| Free Cash Flow | -15.77M |
| FCF Per Share | -0.56 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
IMMX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for IMMX is $7, which is 319.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 319.2% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Scores
| Altman Z-Score | -4.34 |
| Piotroski F-Score | 1 |